• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ladenburg Thalmann initiated coverage on Biodexa Pharmaceuticals PLC with a new price target

    2/8/24 7:21:49 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDRX alert in real time by email
    Ladenburg Thalmann initiated coverage of Biodexa Pharmaceuticals PLC with a rating of Buy and set a new price target of $8.00
    Get the next $BDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDRX

    DatePrice TargetRatingAnalyst
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/20/24 11:56:39 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/14/24 5:12:47 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/12/24 4:30:48 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

      June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ("T1D"). The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and

      6/4/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shareholder Update

      May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. Financial positionAs of May 29, 2025, the Company had access to the following cash resources:   $ millionsCash at bank 5.7Cash in escrow for eRapa Phase 3 program 4.4  10.1   Undrawn CPRIT grant for eRapa Phase 3 program 11.9   Debt 0.5 The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded. Based on its latest projections,

      5/30/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General Meeting

      May 22, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Notice of General Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is proposing four resolutions: Ordinary Resolutions       1.   That, subject to and conditional on the passing of Resolution 4, each of the issued ordinary shares of £0.001 each in the capital of the Comp

      5/22/25 4:30:00 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

      March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the appointment of Precision for Medicine, LLC ("Precision") as the clinical research organization ("CRO") to conduct the European component of the upcoming registrational Phase 3

      3/6/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • Biodexa Appoints Ann Merchant to the Board of Directors

      Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa

      12/29/23 4:05:00 AM ET
      $ALVO
      $BDRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BDRX
    Financials

    Live finance-specific insights

    See more
    • Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

      CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call

      11/21/24 7:35:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Biodexa Pharmaceuticals PLC with a new price target

      Ladenburg Thalmann initiated coverage of Biodexa Pharmaceuticals PLC with a rating of Buy and set a new price target of $8.00

      2/8/24 7:21:49 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    SEC Filings

    See more
    • SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/4/25 8:30:26 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/2/25 5:24:24 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/2/25 5:23:46 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care